FDA approves TOBI Podhaler to treat a type of bacterial lung infection in cystic fibrosis patients HEALTH U.S. FDA approves TOBI Podhaler to treat a type of bacterial lung infection in cystic fibrosis patients Redazione 23 Marzo 2013 The U.S. Food and Drug Administration approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic... Per saperne di piรน Maggiori informazioni su FDA approves TOBI Podhaler to treat a type of bacterial lung infection in cystic fibrosis patients